Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite

Lipella Pharmaceuticals, Inc. has entered into a manufacturing collaboration agreement with Cook MyoSite, Inc. to facilitate Chemistry, Manufacturing, and Control documentation for Lipella’s drug candidate LP-10, aimed at treating hemorrhagic cystitis. LP-10 has been granted Orphan Drug Designation by the FDA.